WEKO3
アイテム
{"_buckets": {"deposit": "257ebaeb-0752-4539-9498-57480ae3826d"}, "_deposit": {"id": "49478", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "49478"}, "status": "published"}, "_oai": {"id": "oai:tsukuba.repo.nii.ac.jp:00049478", "sets": ["919", "5104", "3353", "970", "7336"]}, "item_5_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2018-09", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3", "bibliographicPageEnd": "632", "bibliographicPageStart": "622", "bibliographicVolumeNumber": "11", "bibliographic_titles": [{}, {"bibliographic_title": "Case Reports in Oncology", "bibliographic_titleLang": "en"}]}]}, "item_5_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Background: Sensitive-relapsed small-cell lung cancer (SCLC) is thought to be sensitive to chemotherapy; therefore, second-line chemotherapy is recommended. Although platinum rechallenge is performed in the second-line chemotherapy for sensitive-relapsed SCLC, it remains unclear whether such a strategy is effective. Methods: We retrospectively analyzed the outcome of rechallenge chemotherapy for sensitive-relapsed SCLC. The endpoints of this study were progression-free survival from the time of relapse (PFS-Re) and overall survival from the time of relapse (OS-Re). We also compared the toxicity profile of rechallenge chemotherapy to that of first-line chemotherapy. Results: Of the 133 SCLC patients who received first-line treatment, 20 patients satisfied the definition of sensitive relapse and received rechallenge chemotherapy. Combined carboplatin and etoposide was the most commonly used rechallenge regimen, and 17 (85%) received it at a reduced dose due to hematological toxicity during the first-line treatment. Median PFS-Re and OS-Re were 4.5 months (95% CI: 3.5–5.4) and 10.5 months (95% CI: 7.9–13.0), respectively. There was no association between dose adjustment and survival. The frequency of hematologic toxicity tended to be lower with rechallenge than first-line treatment. The incidence of grade 3 febrile neutropenia decreased from 40% in first-line treatment to 15% in rechallenge. Conclusion: Platinum rechallenge could be a useful second-line option for sensitive-relapsed SCLC, having favorable efficacy and safety. Dose adjustment at rechallenge based on the toxicity profile during the first-line chemotherapy could reduce toxicity without weakening efficacy.", "subitem_description_type": "Abstract"}]}, "item_5_publisher_27": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Karger"}]}, "item_5_relation_10": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "30323752", "subitem_relation_type_select": "PMID"}}]}, "item_5_relation_11": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1159/000492780", "subitem_relation_type_select": "DOI"}}]}, "item_5_rights_12": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© 2018 The Author(s) Published by S. Karger AG, Basel www.karger.com/cro"}, {"subitem_rights": "This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission."}]}, "item_5_select_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_5_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1662-6575", "subitem_source_identifier_type": "ISSN"}]}, "item_5_source_id_9": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AA12780955", "subitem_source_identifier_type": "NCID"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "関根, 郁夫"}, {"creatorName": "セキネ, イクオ", "creatorNameLang": "ja-Kana"}, {"creatorName": "SEKINE, Ikuo", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "130572", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "10508310", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://nrid.nii.ac.jp/ja/nrid/1000010508310"}, {"nameIdentifier": "0000003751", "nameIdentifierScheme": "筑波大学研究者総覧", "nameIdentifierURI": "http://trios.tsukuba.ac.jp/researcher/0000003751"}]}, {"creatorNames": [{"creatorName": "中澤, 健介"}, {"creatorName": "ナカザワ, ケンスケ", "creatorNameLang": "ja-Kana"}, {"creatorName": "NAKAZAWA, Kensuke", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "204593", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "40757796", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://nrid.nii.ac.jp/ja/nrid/1000040757796"}, {"nameIdentifier": "0000003776", "nameIdentifierScheme": "筑波大学研究者総覧", "nameIdentifierURI": "http://trios.tsukuba.ac.jp/researcher/0000003776"}]}, {"creatorNames": [{"creatorName": "佐藤, 浩昭"}, {"creatorName": "サトウ, ヒロアキ", "creatorNameLang": "ja-Kana"}, {"creatorName": "SATOH, Hiroaki", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "347", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "00261800", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://nrid.nii.ac.jp/ja/nrid/1000000261800"}, {"nameIdentifier": "0000001747", "nameIdentifierScheme": "筑波大学研究者総覧", "nameIdentifierURI": "http://trios.tsukuba.ac.jp/researcher/0000001747"}]}, {"creatorNames": [{"creatorName": "檜澤, 伸之"}, {"creatorName": "ヒザワ, ノブユキ", "creatorNameLang": "ja-Kana"}, {"creatorName": "HIZAWA, Nobuyuki", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "106745", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "00301896", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://nrid.nii.ac.jp/ja/nrid/1000000301896"}, {"nameIdentifier": "0000001898", "nameIdentifierScheme": "筑波大学研究者総覧", "nameIdentifierURI": "http://trios.tsukuba.ac.jp/researcher/0000001898"}]}, {"creatorNames": [{"creatorName": "Shiozawa, Toshihiro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "207721", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Aida, Yuka", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "207722", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Watanabe, Hiroko", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "207723", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kurishima, Koichi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "207725", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-04-04"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "CRO_11-3.pdf", "filesize": [{"value": "962.5 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_9", "mimetype": "application/pdf", "size": 962500.0, "url": {"label": "CRO_11-3", "url": "https://tsukuba.repo.nii.ac.jp/record/49478/files/CRO_11-3.pdf"}, "version_id": "02f0e477-adae-433f-a0b5-aac53824eeff"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Rechallenge with First-Line Platinum Chemotherapy for Sensitive-Relapsed Small-Cell Lung Cancer", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Rechallenge with First-Line Platinum Chemotherapy for Sensitive-Relapsed Small-Cell Lung Cancer"}]}, "item_type_id": "5", "owner": "1", "path": ["919", "5104", "3353", "970", "7336"], "permalink_uri": "http://hdl.handle.net/2241/00154946", "pubdate": {"attribute_name": "公開日", "attribute_value": "2019-04-04"}, "publish_date": "2019-04-04", "publish_status": "0", "recid": "49478", "relation": {}, "relation_version_is_last": true, "title": ["Rechallenge with First-Line Platinum Chemotherapy for Sensitive-Relapsed Small-Cell Lung Cancer"], "weko_shared_id": 5}
Rechallenge with First-Line Platinum Chemotherapy for Sensitive-Relapsed Small-Cell Lung Cancer
http://hdl.handle.net/2241/00154946
http://hdl.handle.net/2241/001549460d7abae1-145c-41a2-8504-b38a4d8e1cd9
名前 / ファイル | ライセンス | アクション |
---|---|---|
CRO_11-3 (962.5 kB)
|
Item type | Journal Article(1) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
公開日 | 2019-04-04 | |||||||||||
タイトル | ||||||||||||
タイトル | Rechallenge with First-Line Platinum Chemotherapy for Sensitive-Relapsed Small-Cell Lung Cancer | |||||||||||
言語 | ||||||||||||
言語 | eng | |||||||||||
資源タイプ | ||||||||||||
資源 | http://purl.org/coar/resource_type/c_6501 | |||||||||||
タイプ | journal article | |||||||||||
著者 |
関根, 郁夫
× 関根, 郁夫× 中澤, 健介
WEKO
204593
× 佐藤, 浩昭× 檜澤, 伸之× Shiozawa, Toshihiro× Aida, Yuka× Watanabe, Hiroko× Kurishima, Koichi |
|||||||||||
抄録 | ||||||||||||
内容記述タイプ | Abstract | |||||||||||
内容記述 | Background: Sensitive-relapsed small-cell lung cancer (SCLC) is thought to be sensitive to chemotherapy; therefore, second-line chemotherapy is recommended. Although platinum rechallenge is performed in the second-line chemotherapy for sensitive-relapsed SCLC, it remains unclear whether such a strategy is effective. Methods: We retrospectively analyzed the outcome of rechallenge chemotherapy for sensitive-relapsed SCLC. The endpoints of this study were progression-free survival from the time of relapse (PFS-Re) and overall survival from the time of relapse (OS-Re). We also compared the toxicity profile of rechallenge chemotherapy to that of first-line chemotherapy. Results: Of the 133 SCLC patients who received first-line treatment, 20 patients satisfied the definition of sensitive relapse and received rechallenge chemotherapy. Combined carboplatin and etoposide was the most commonly used rechallenge regimen, and 17 (85%) received it at a reduced dose due to hematological toxicity during the first-line treatment. Median PFS-Re and OS-Re were 4.5 months (95% CI: 3.5–5.4) and 10.5 months (95% CI: 7.9–13.0), respectively. There was no association between dose adjustment and survival. The frequency of hematologic toxicity tended to be lower with rechallenge than first-line treatment. The incidence of grade 3 febrile neutropenia decreased from 40% in first-line treatment to 15% in rechallenge. Conclusion: Platinum rechallenge could be a useful second-line option for sensitive-relapsed SCLC, having favorable efficacy and safety. Dose adjustment at rechallenge based on the toxicity profile during the first-line chemotherapy could reduce toxicity without weakening efficacy. | |||||||||||
書誌情報 |
en : Case Reports in Oncology 巻 11, 号 3, p. 622-632, 発行日 2018-09 |
|||||||||||
ISSN | ||||||||||||
収録物識別子タイプ | ISSN | |||||||||||
収録物識別子 | 1662-6575 | |||||||||||
書誌レコードID | ||||||||||||
収録物識別子タイプ | NCID | |||||||||||
収録物識別子 | AA12780955 | |||||||||||
PubMed番号 | ||||||||||||
識別子タイプ | PMID | |||||||||||
関連識別子 | 30323752 | |||||||||||
DOI | ||||||||||||
識別子タイプ | DOI | |||||||||||
関連識別子 | 10.1159/000492780 | |||||||||||
権利 | ||||||||||||
権利情報 | © 2018 The Author(s) Published by S. Karger AG, Basel www.karger.com/cro | |||||||||||
権利 | ||||||||||||
権利情報 | This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. | |||||||||||
著者版フラグ | ||||||||||||
値 | publisher | |||||||||||
出版者 | ||||||||||||
出版者 | Karger |